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Statins in acute 
glomerulonephritis
Statins, the class of popular cholesterol-
lowering drugs, have eff ects that seem to 
be independent of their lipid-lowering 
action. In particular, statins have been 
shown to reduce the infl ammatory 
response to atherosclerosis, now 
considered to be a critical determinant in 
the progression of glomerulonephritis. 
Christensen et al. studied the 
eff ects of statins on the severity and 
progression of glomerulonephritis 
in mice. Acute nephrotoxic serum 
nephritis was induced in mice. Th e 
animals were treated with simvastatin 
prophylactically during the induction 
or immediately aft er onset of the 
disease. Prophylactic simvastatin 
treatment reduced infl ammation and 
ameliorated the histological changes of 
acute glomerulonephritis induced by 
the nephrotoxic serum. However, aft er 
the disease was established, there was 
no benefi cial eff ect of the drug. Statins 
achieve their salutary eff ect by blocking 
the conversion of hydroxymethylglutaryl 
coenzyme A to mevalonic acid, a critical 
intermediate in cholesterol biosynthesis. 
Repletion of mevalonate prevented 
the protective eff ect of the statin on 
glomerular infl ammation and renal 
failure. Th ese results might explain the 
benefi cial eff ects seen in many other 
infl ammatory conditions with the use of 
statins. See page 457. 
FGF-23  parathyroid 
hormone in renal 
failure
Osteomalacia, oft en referred to as 
“paraneoplastic syndrome,” generated 
much excitement when one of the 
factors that cause this syndrome was 
found to be the hormone fi broblast 
growth factor-23 (FGF-23). Th is factor 
acts on the kidney to reduce phosphate 
reabsorption and cause phosphate 
excretion and hypophosphatemia. Its 
regulation is now a hot area of study. 
Nagano et al. found that rats with 
severe, chronic renal failure developed 
the expected high phosphate, high 
parathyroid hormone, and low active 
vitamin D levels. Th e animals also had 
very high FGF-23 levels. Feeding them 
phosphate binders not only reduced 
their phosphate levels but decreased 
their FGF-23 and parathyroid hormone 
levels as well. Clearly, the rise in FGF-23 
levels was not due to retention of this 
hormone, as glomerular fi ltration rates 
decreased; rather, it seemed to respond 
to serum phosphate concentrations. 
Whether the response was directly 
related to the change in serum 
phosphate, the concomitant reduction 
in parathyroid hormone, or even the 
increase in serum ionized calcium 
and vitamin D levels requires more 
studies. Nonetheless, it is interesting 
that a hormone that controls phosphate 
excretion responds to serum phosphate 
levels. See page 531.
Risk and benefit to the 
heart during kidney 
disease
As the kidney fails, cardiovascular 
risk assumes a greater role in causing 
morbidity. Strategies for prevention 
of cardiovascular risk are well known; 
control of hypertension, reduction 
of salt intake (or, barring that, use 
of diuretics to reduce volume) and 
control of hypercholesterolemia are not 
considered to be rocket science. Th e 
question is whether these preventive 
strategies are being practiced. An 
article by DeNicola et al. suggests 
that we have a long way to go. Th ey 
studied predialysis patients followed 
in 26 renal clinics in Italy. Th ey found 
that only 12% of the patients had 
well-controlled blood pressure, only 
19% were on a low-salt diet and 78% 
were not receiving statins. In addition, 
patients with diabetes were less likely 
to be properly treated. More aggressive 
education campaigns are needed to 
make sure that cardiovascular risk is 
controlled in all patients with renal 
disease. See page 538.
Don’t discard kidneys 
from marginal donors
Th e shortage of kidneys for organ 
transplantation is so severe that many 
centers are searching for organs from 
donors who, until recently, would not 
have been considered. Donors with 
impaired plasma creatinine, severe 
hemodynamic impairment, advanced 
age, or atherosclerosis were refused 
by two or more centers in the Île-
de-France region in France but were 
eventually accepted by other centers 
in the same region. Dhamme et al. 
retrospectively analyzed the results of 
transplantation of these kidneys from 
marginal donors as compared with a 
control group of kidneys taken from 
donors that had been accepted by all 
centers in the region. Th ey found, as 
expected, that the marginal kidneys 
with elevated creatinine clearances 
failed to function immediately 
about twice as oft en as those kidneys 
with lower creatinine clearances. 
Yet the overall survival rate of both 
normal and marginal kidneys (77% 
versus 70%) and patients (88% for 
both groups) aft er 5 years was not 
statistically diff erent. Although the 
number of these transplants was small 
(170 for each group over a period of 6 
years), the outcomes are encouraging. 
See page 546. 
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